COMMITTED TO DISCOVERING BEST-IN-CLASS THERAPIES
TO CONQUER INFLAMMATORY and immunologic DISEASES

RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis

March 22, 2021



« back to news page